ProCE Banner Activity

Alliance A041703: Phase II Trial of Inotuzumab Ozogamicin Induction Followed by Blinatumomab Consolidation for Older Adults With Newly Diagnosed Ph-Negative, CD22-Positive B-ALL

Conference Coverage
Slideset

Induction with inotuzumab ozogamicin followed by blinatumomab consolidation was associated with a 1-year EFS rate of 75% in older adults with newly diagnosed Ph-negative, CD22-positive B-ALL.

Released: June 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis